Ambrilia Biopharma Inc. Validates its Targeted Delivery Technology for Cancer in Vivo

MONTREAL, QUEBEC--(Marketwire - June 19, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) today reported that it demonstrated and validated the in vivo proof-of-concept with its NGR-delivery technology applied to a carrier containing a siRNA (small interfering RNA). Data in animal tumor models showed efficient siRNA delivery to the tumor tissue, internalization and suppression of a cancer-promoting gene (oncogene). Such genes are essential to the growth of a number of tumors. In the past years, a number of oncogenes have been suppressed with RNA interference (RNAi), which can be achieved by siRNAs, showing the potential for therapeutic applications in humans.